Table 3. Cumulative Incidence of Drug Discontinuation in the First 12 Months of Therapy by Eligibility and Stop Reason.
| Stop Reason | Etanercept, Mean % (95% CI) | Adalimumab, Mean % (95% CI) | Ustekinumab, Mean % (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Eligible | Ineligible | i-PASI | Eligible | Ineligible | i-PASI | Eligible | Ineligible | i-PASI | |
| Adverse events | 3 (2-4) | 4 (3-6) | 2 (1-5) | 3 (3-4) | 5 (3-7) | 3 (2-4) | 3 (2-4) | 2 (1-3) | 2 (1-4) |
| Ineffectiveness | 11 (9-13) | 15 (12-19) | 15 (11-20) | 8 (7-9) | 6 (4-9) | 7 (5-9) | 3 (2-4) | 5 (3-7) | 3 (2-5) |
| Other | 4 (3-5) | 2 (1-3) | 4 (2-8) | 2 (2-3) | 5 (3-7) | 3 (2-4) | 2 (1-3) | 2 (1-3) | 2 (1-4) |
| Missing | 4 (3-5) | 6 (4-8) | 8 (5-13) | 3 (2-4) | 2 (1-3) | 2 (1-3) | 1 (0-1) | 2 (1-4) | 2 (1-3) |
Abbreviation: i-PASI, insufficient baseline Psoriasis Area and Severity Index.